We are live on ! Find out more
BAMS

Bellevue Asset Management (Switzerland) Portfolio holdings

AUM $656M
1-Year Est. Return 11.45%
This Fund
S&P 500
This Quarter Est. Return
-14.54%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$613M
AUM Growth
-$108M
Cap. Flow
+$11.4M
Cap. Flow %
1.86%
Top 10 Hldgs %
30.19%
Holding
150
New
11
Increased
47
Reduced
31
Closed
17

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$5.95M
2
LRMR icon
Larimar Therapeutics
LRMR
+$3.76M
3
AMGN icon
Amgen
AMGN
+$3.65M
4
INSY
Insys Therapeutics, Inc.
INSY
+$3.31M
5
HALO icon
Halozyme
HALO
+$3.1M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$6.46M
2
CAH icon
Cardinal Health
CAH
+$3.59M
3
KITE
Kite Pharma, Inc.
KITE
+$3.49M
4
MDVN
MEDIVATION, INC.
MDVN
+$3.47M
5
ALKS icon
Alkermes
ALKS
+$3.33M

Sector Composition

Rank Sector Weight
1 Healthcare 91.86%
2 Financials 0.95%
3 Industrials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMO icon
76
Thermo Fisher Scientific
TMO
$222B
$2.45M 0.4%
20,000
+7,000
+54% +$912K
HTWR
77
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$2.35M 0.38%
45,000
+23,000
+105% +$1.75M
TFX icon
78
Teleflex
TFX
$6B
$2.31M 0.38%
18,557
-11,443
-38% -$1.53M
NVAX icon
79
Novavax
NVAX
$1.31B
$2.3M 0.37%
16,250
-9,750
-38% -$2.19M
MDVN
80
DELISTED
MEDIVATION, INC.
MDVN
$2.24M 0.36%
52,600
-70,000
-57% -$3.47M
HCSG icon
81
Healthcare Services Group
HCSG
$1.49B
$2.19M 0.36%
65,000
– –
NUVA
82
DELISTED
NuVasive, Inc.
NUVA
$2.17M 0.35%
45,000
– –
QGENF
83
DELISTED
QIAGEN NV
QGENF
$2.06M 0.34%
80,000
+20,000
+33% +$516K
UBIO
84
DELISTED
Proshares UltraPro NASDAQ Biotechnology
UBIO
$2.04M 0.33%
+7,000
New +$568K
ACAD icon
85
Acadia Pharmaceuticals
ACAD
$5.05B
$1.95M 0.32%
59,000
-42,000
-42% -$1.75M
SGEN
86
DELISTED
Seagen Inc. Common Stock
SGEN
$1.85M 0.3%
48,000
+8,000
+20% +$360K
GMED icon
87
Globus Medical
GMED
$11.6B
$1.81M 0.3%
87,700
– –
MGNX icon
88
MacroGenics
MGNX
$263M
$1.78M 0.29%
83,000
+2,000
+2% +$62.7K
BLUE
89
DELISTED
bluebird bio
BLUE
$1.75M 0.29%
1,583
+39
+3% +$71.1K
WCG
90
DELISTED
Wellcare Health Plans, Inc.
WCG
$1.72M 0.28%
20,000
– –
CLDX icon
91
Celldex Therapeutics
CLDX
$3.35B
$1.69M 0.28%
10,667
+5,734
+116% +$1.62M
BAX icon
92
Baxter International
BAX
$14.3B
$1.64M 0.27%
+50,000
New +$1.89M
INO icon
93
Inovio Pharmaceuticals
INO
$83.2M
$1.53M 0.25%
22,083
+5,416
+32% +$472K
ABBV icon
94
AbbVie
ABBV
$440B
$1.47M 0.24%
27,000
– –
DVA icon
95
DaVita
DVA
$11.9B
$1.45M 0.24%
20,000
-6,000
-23% -$465K
ICPT
96
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.44M 0.24%
8,700
+1,200
+16% +$264K
ALDR
97
DELISTED
Alder Biopharmaceuticals
ALDR
$1.41M 0.23%
+43,000
New +$1.83M
JUNO
98
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.34M 0.22%
33,000
-15,000
-31% -$658K
ANGO icon
99
AngioDynamics
ANGO
$653M
$1.32M 0.22%
100,000
– –
MYGN icon
100
Myriad Genetics
MYGN
$305M
$1.24M 0.2%
33,000
-5,000
-13% -$177K
2 3
4
5 6

Similar funds

VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
MSU
Maple Securities USA Jersey City, New Jersey $672M AUM 1.03% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.5% 1-Year Est. Return
SFP
Santa Fe Partners Santa Fe, New Mexico $608M AUM 8.76% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return
NMIS
Northwestern Mutual Investment Services Milwaukee, Wisconsin $525M AUM 2.45% 1-Year Est. Return
SM
Stratton Management King Of Prussia, Pennsylvania $824M AUM 1.57% 1-Year Est. Return
ZAM
Zenit Asset Management Stockholm, Sweden $450M AUM 8.32% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s Q3 2015 Portfolio in Review

As of Q3 2015, Bellevue Asset Management (Switzerland) held 150 positions worth $613M, down 15% from $721M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Asset Management (Switzerland)'s Q3 2015 filing shows 11 new, 47 increased, 31 reduced and 17 closed positions. Its largest new stake was Supernus Pharmaceuticals: 320,000 shares worth $4.49M. The largest sale was RECEPTOS INC COM STK (DE), an estimated $6.46M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Asset Management (Switzerland)'s largest Q3 2015 buy was Supernus Pharmaceuticals: 320,000 shares worth $4.49M.
  • Bellevue Asset Management (Switzerland) added most to Amgen in Q3 2015, an estimated $3.65M increase.
  • Bellevue Asset Management (Switzerland)'s biggest Q3 2015 reduction was Cardinal Health, cutting an estimated $3.59M.
  • Bellevue Asset Management (Switzerland) fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $6.46M.
  • Bellevue Asset Management (Switzerland)'s ten largest holdings make up 30% of its $613M portfolio in Q3 2015.
  • Bellevue Asset Management (Switzerland) opened 11 new positions and closed 17 in Q3 2015.
  • Bellevue Asset Management (Switzerland)'s portfolio value fell 15% quarter-over-quarter to $613M.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q3 2015, filed 12 Nov 2015.